Neurology
4 drugs are in development for Acromegaly.
- Companies
- 3
- Clinical trials
- 5
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Acromegaly pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
Phase 3(2)
| Drug | Company |
|---|---|
| mycapssa | CHIASMA, INC (CHMA) |
| Paltusotine | Crinetics Pharmaceuticals, Inc. (CRNX) |
Preclinical(1)
| Drug | Company |
|---|---|
| veldoreotide | Strongbridge Biopharma plc (SBBP) |
About this indication
Acromegaly context
Neurology·MeSH: Acromegaly (D000172)
Also known as: Hypersecretion Syndrome, Somatotropin (Acromegaly), Inappropriate GH Secretion Syndrome (Acromegaly), Inappropriate Growth Hormone Secretion Syndrome (Acromegaly), Somatotropin Hypersecretion Syndromes (Acromegaly)
Frequently asked questions
How many drugs are in development for Acromegaly?
BioSniper tracks 4 drugs in development for Acromegaly across 3 companies.
How many clinical trials target Acromegaly?
There are 5 clinical trials targeting Acromegaly tracked by BioSniper.